Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / South Africa

Coordination and Support Action · Running

CTCAN Clinical Trials Community Africa Network

Coordinator
Nuvoteq (pty) Ltd, South Africa
Runs
1 May 2023 to 31 October 2025
Status
Running
EU funding
€1.2m
Total cost
€2.5m
Partners
9 organisations in 6 countries
Type
Coordination and Support Action
Grant agreement
101103299

What the project is doing

In the project's own words, from its summary on CORDIS.

With over 25% of the global disease burden, only 3% of global clinical trials occur in Africa. This disproportion is driven by inadequacies in clinical research capacity, regulatory process ambiguity, deficient regional patient and disease area data, and lack of visibility of existing clinical research capabilities in Africa. To address this disproportion, this proposal seeks to establish the Clinical Trials Community Africa Network (CTCAN), a collaborative framework of key clinical research stakeholders in the African region, pharma partners, and other relevant international stakeholders, with the overarching goal of bringing more clinical trials to the region in a sustainable and coordinated manner.

This collaboration will map and draw on the experience and expertise of already existing networks and initiatives. It will create a network of subnetworks that will foster coordination in clinical research, by ensuring and encouraging alignment in disease area prioritization, raising awareness and visibility of existing capacity from sites and labs across Africa, operationalising the regulatory processes across the region, and strengthen less experienced sites and labs through a clinical trial preparedness framework, while encouraging inter- and cross-continental knowledge and expertise sharing.

CTCAN will use and expand the Clinical Trials Community (CTC) platform, an electronic platform consolidating data on researchers, regulations, sites, and epidemiology across the continent. The result will be an ever-present and ready-to-go pool of clinical research sites and labs with the agility to rapidly address new and emerging global health threats, epidemics, and pandemics, thereby efficiently contributing towards clinical research in pandemic preparedness.

CTCAN will lay the foundation for a sustainable network of clinical trial sites and laboratories in sub-Saharan Africa by leveraging and initiating collaboration between existing sub-networks, funders, and pharma.

Topics

Who is involved

OrganisationCityCountryRole
Nuvoteq (pty) LtdGautengSouth AfricaCoordinator
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Janssen Cilag SAMadridSpainAssociatedpartner
Fondation MerieuxLyonFranceParticipant
Medicines Development for Global Health LimitedElyUnited KingdomAssociatedpartner
Bio Ventures for Global HealthSeattleUnited StatesAssociatedpartner
Janssen Research & Development, LLCRaritanUnited StatesAssociatedpartner
Johnson & Johnson Services, Inc.New BrunswickUnited StatesAssociatedpartner
Science for Africa FoundationWilmingtonUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI